12
Sun, Jul

remdesivir

  • Today, the U.S. Food and Drug Administration issued an emergency use authorization for the investigational antiviral drug remdesivir for the treatment of suspected or laboratory-confirmed COVID-19 in adults and children hospitalized with severe disease. While there is limited information known about the safety and effectiveness of using remdesivir to treat people in the hospital with COVID-19, the investigational drug was shown in a clinical trial to shorten the time to recovery in some patients.

  • Convalescent plasma (CP) is the term used for plasma that is removed from the blood of a person who has recovered from a disease, then transfused into a patient still battling it.

    The Food and Drugs Authority (FDA) has approved an investigational convalescent plasma collected from individuals who have recovered from COVID-19 for the treatment of critically ill COVID-19 patients.

  • The agency said the drug has not been approved as a general treatment for COVID-19. Rather, it is only intended for emergency use on severely ill patients who have been hospitalized.

     The U.S. Food and Drug Administration on Friday granted emergency use authorization for the antiviral remdesivir to treat COVID-19.

  • The price tag is slightly below the range of $2,520 to $2,800 suggested last week by U.S. drug pricing research group the Institute for Clinical and Economic Review (ICER) after British researchers said they found that the cheap, widely available steroid dexamethasone significantly reduced mortality among severely ill COVID-19 patients.

    Gilead Sciences Inc on Monday priced its COVID-19 antiviral remdesivir at $2,340 per patient for wealthier nations and agreed to send nearly all of its supply of the drug to the United States over the next three months.

  • Meanwhile, the drug also seemed to benefit patients who required oxygen assistance without mechanical ventilation, reducing deaths in this group by about 20%.

    As the world awaits a COVID-19 vaccine, researchers studying possible treatments have found a commonly used steroid called dexamethasone that might help save one-third of patients who end up on ventilators.

  • Trial results announced on Tuesday showed dexamethasone, used since the 1960s to reduce inflammation in diseases such as arthritis, cut death rates by around a third among the most severely ill COVID-19 patients admitted to hospital.

    The World Health Organization (WHO) said it was moving to update its guidelines on treating people stricken with COVID-19 to reflect results of a clinical trial that showed a cheap, common steroid can help save critically ill patients.

Sign up via our free email subscription service to receive notifications when new information is available.